Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
TransEnterix said yesterday that it’s looking for $50 million from a follow-on offering of common stock to finance the sales and marketing of its SurgiBot robot-assisted surgery device.
The Research Triangle Park, N.C.-based company has not yet revealed the amount of shares, share price or date the offering will open. Read more
Outset Medical, previously Home Dialysis Plus, said it raised $91 million in a new funding round, with $51 million in equity and $40 million in debt funding. Funds are slated to continue development and promotion of its Tablo all-in-one dialysis system.
The $51 million round of equity funding was led by new investor Fidelity Research and Management Co., joined by new investors Partner Fund Management LP, Perceptive Advisors and CRG, and prior backers Warburg Pincus and The Vertical Group, Outset Medical said. The $40 million in debt financing was led by CRG. Read more
Big data – from electronic health records, bio-feedback from wearables and remote monitoring systems that communicate with medical implants – is changing how medical devices are created and designed.
MassDevice.com spoke to a pair of researchers at Battelle – David Giles, senior director of medical devices and health analytics and Stephanie Kute, platform lead for the Battelle analytics and health research team – about their experiences with big data and how it’s changing the world of medical devices. Read more